Evofem Biosciences, Inc. is a biopharmaceutical company located in San Diego, California. Founded in 2015, the company is focused on providing solutions to unmet needs in women’s sexual and reproductive health. They currently have 35 full-time employees and are publicly traded on Nasdaq under the stock symbol EVFM.
Leading Evofem Biosciences’ mission is to empower women to make confident choices and take control of their sexual and reproductive health. The company works to develop products that offer innovative solutions to improve the quality of care and quality of life for women.
Evofem Biosciences’ primary product is Phexxi, a non-hormonal, pH-based, contraceptive vaginal gel that is available without a prescription. Phexxi offers women a convenient, safe, and effective option for contraception. Beyond Phexxi, the company is also developing EVO100 for the prevention of chlamydia and gonorrhea in women, and EVO200 for the prevention of recurrent bacterial vaginosis.
Evofem Biosciences is dedicated to making a difference in the lives of women in the United States and globally. Through their research and development of sexual and reproductive health solutions, Evofem Biosciences seeks to provide women with the opportunity to make informed, empowered choices about their sexual and reproductive health.
Evofem Biosciences, Inc. (EVFM) is a biopharmaceutical company that develops and commercializes novel products and technologies designed to address unmet needs in women’s sexual and reproductive health.
The company has had a difficult start and is currently performing below analyst expectations. However, EVFM continues to work diligently towards delivering positive results for its shareholders. Its current earnings growth is not available, but its gross profit was reported to be $12,422,000 in the most recent fiscal year, up from the prior year. EVFM has also experienced a 36.70% revenue growth in the same period.
EVFM’s free cash flow is a particularly negative metric, reported as -$43,161,124 in the most recent fiscal year. EVFM also has a return on assets of -121.22%, indicating that its expenses and liabilities are greater than its assets by a large margin.
EVFM’s total revenue as reported in the most recent fiscal year was $18,395,000, which signifies a marginal improvement from the prior year. Additionally, its current price stands at $0.76, with a target low price set at $225. Its current ratio is .21, while its quick ratio stands at .10. Quick ratios measure the ability of a company to cover its short-term debts.
EVFM’s gross margins stand at 74.31%, highlighting the efficiency of the company in managing its costs. On the other hand, its operating margin is -319.51%, indicating that its operational expenses are outweighing its revenues.
EVFM has a total cash of $639,000 as reported in its most recent fiscal year. This figure is coupled with total cash per share of $0.28. Its profit margin and return on equity are -256.40% and not available, respectively.
Overall, EVFM has struggled to perform to industry standards, exhibiting weak financial metrics. However, its stock is rated as a “buy” by one analyst. The median and mean price target for the stock is set at $225.
During a recession, companies like Evofem Biosciences often experience reduced demand for their products due to a decrease in disposable income, as well as a lack of access to medical insurance for potential consumers. Despite these challenges, Evofem Biosciences has maintained a focus on innovating their product portfolio to ensure they continue to meet the changing needs of their customers.
The company has taken steps to reduce its overhead expenses, such as cutting back on non-essential travel and marketing spending, while continuing to hire talented personnel, invest in technology and research, and launch products that appeal to their customer base. To help with cash flow constraints, the company has also taken steps to apply for and secure loans and lines of credit, as needed.
Evofem Biosciences has also invested in their digital health platform, enabling consumers to order and access products more easily using their mobile devices. This has allowed the company to widen their reach and maintain a strong presence during this difficult economic period.
Overall, while recessionary periods can pose significant challenges to any company, Evofem Biosciences has managed to stay afloat and continue to expand its reach among its customer base. The company’s commitment to providing innovative and effective solutions to the women’s health market is a testament to its resilience during a time of economic uncertainty.
In the face of high inflation, a company’s performance largely depends on how well it is able to manage its resources, costs, and risks. To succeed during periods of high inflation, Evofem Biosciences has adopted a cost-containment model that prioritizes prudent spending and efficient production. This has allowed the company to keep production costs down and continued investment in research and development of sexual and reproductive health solutions.
Evofem Biosciences has also created innovative strategies for product pricing, such as establishing a Medicare Part D rebate program for Phexxi and introducing price protection for treatment providers and patients. This has allowed the company to remain competitive in the market, while making sure that the cost of their treatments remains affordable to consumers.
The company has also leveraged external collaborations to help finance the development of their products. By collaborating with research universities, research institutes, healthcare providers, government agencies, and venture capitalists, Evofem Biosciences has been able to secure the resources necessary to continue developing sexual and reproductive health solutions.
In addition to cost containment strategies, Evofem Biosciences has also implemented operational procedures to help manage risk levels during periods of high inflation. The company has strived for transparency in their operations, while also focusing on risk management. This has enabled the company to better anticipate, prepare for, and respond to external economic changes.
All in all, Evofem Biosciences has adopted a series of strategies and policies to ensure that it is able to remain competitive and successful during periods of high inflation. With their cost-containment model, product pricing strategies, external collaborations, and operational risk management procedures, the company has been able to maintain its profitability despite times of economic uncertainty.
The risks associated with investing in EVFM’s stock include the potential for a market downturn, competitive pressures from large pharmaceutical companies, regulatory changes, delayed product development, and cost overruns. Additionally, EVFM’s financial performance could continue to suffer if the company fails to adequately develop its new products. Lastly, EVFM does not provide any dividends, which could make investing in the company’s stock more difficult.